ChemicalBook > CAS DataBase List > Tislelizumab
Tislelizumab
- Product Name
- Tislelizumab
- CAS No.
- 1858168-59-8
- Chemical Name
- Tislelizumab
- Synonyms
- Tislelizumab;Research Grade Tislelizumab(DHH02206)
- CBNumber
- CB28081045
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Tislelizumab Property
- storage temp.
- Store at -20°C
- form
- Liquid
- color
- Colorless to light yellow
Tislelizumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Tislelizumab Suppliers
- Tel
- 17754423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8011
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10457
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24644
- Advantage
- 58
- Tel
- 027-65279366 18108604862
- products@biolabreagent.com
- Country
- China
- ProdList
- 9818
- Advantage
- 58
- Tel
- 13720134139 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 5825
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11974
- Advantage
- 58
- Tel
- 17721492509
- 643638326@qq.com
- Country
- China
- ProdList
- 5345
- Advantage
- 58
- Tel
- 18670069958 18670069958
- 3062105966@qq.com
- Country
- China
- ProdList
- 3343
- Advantage
- 58
- Tel
- 17316404525
- 209533805@qq.com
- Country
- China
- ProdList
- 9909
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
- Tel
- +8613720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 5221
- Advantage
- 58
- Tel
- +86-057181025280; +8617767106207
- Fax
- 0571-85806285
- sales@molcore.com
- Country
- China
- ProdList
- 49734
- Advantage
- 58
1858168-59-8, TislelizumabRelated Search:
Durvalumab
Denosumab
Evolocumab
Monalizumab
Enfortumab Vedotin
Avelumab
Alirocumab
Nivolumab
Toripalimab
Lambrolizumab